A Chinese pharmaceutical company says the coronavirus vaccine it is developing should be ready by early 2021 for distribution worldwide, including the United States.
Yin Weidong, the CEO of SinoVac, vows to apply to the US Food and Drug Administration to sell CoronaVac in the United States if it passes its third and final round of testing in humans. Yin says he personally has been given the experimental vaccine.
“At the very beginning, our strategy was designed for China and for Wuhan. Soon after that in June and July we adjusted our strategy, that is to face the world,” Yin said, referring to the Chinese city were the virus first emerged.
“Our goal is to provide the vaccine to the world including the US, EU and others,” Yin says.
Stringent regulations in the US, European Union, Japan and Australia have historically blocked the sale of Chinese vaccines. But Yin says that could change.
SinoVac is developing one of China’s top four vaccine candidates along with state-owned SinoPharm, which has two in development, and military-affiliated private firm CanSino.